Real‐world surgical outcomes of a gelatin‐hemostatic matrix in women requiring a hysterectomy: a matched case–control study

Obermair, Helena; Janda, Monika; Obermair, Andreas

doi:10.1111/aogs.12924

Cited by 7 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were published by Obermair, et al [41], who compared adverse events and surgical outcomes of hysterectomy with or without usage of gelatin -thrombin matrix (Surgiflo). Surgiflo neither prevented nor caused additional adverse events in women undergoing hysterectomies [41].…”

Section: Hysterectomysupporting

confidence: 86%

Biologic Hemostatic Agents in Obstetrics and Gynecology

Patriarco¹,

Shenoy²,

Taylor³

2021

Contemporary Applications of Biologic Hemostatic Agents Across Surgical Specialties - Volume 2 [Working Title]

View full text Add to dashboard Cite

In Obstetrics and Gynecology, the practice of biologic hemostatic agents in the field are generally used to augment the basic tenets of hemostasis to decrease the morbidity and mortality of such procedures. These hemostatic agents work along with the body’s physiology to rapidly aid in platelet plug formation, activation of the clotting cascade, the creation of fibrin, and to form a stable clot. The four main sub-categories of hemostatic agents include mechanical, biological, flowable, and fibrin sealants. Mechanical agents act as scaffolding for platelet aggregation to form a platelet plug. Biological agents activate clotting factors in the coagulation cascade to aid in hemostasis. Flowable agents combine biologic with mechanical agents to stabilize clot formation while also providing mechanical tamponade. Fibrin sealants combine high levels of fibrin and thrombin that when combined, form a fibrin clot at an accelerated speed. Hemostatic agents in obstetrics are often used in the setting of postpartum hemorrhage, cesarean delivery and postpartum hysterectomy to decrease the rate of morbidity most commonly seen with abnormal placentation and uterine atony. With gynecologic surgery, hemostatic agents are more commonly used then in obstetrics. They aid in hemostasis with common gynecologic procedures including hysterectomies, ovarian cystectomies, myomectomies, endometriosis cases, incontinence procedures and malignant debulking procedures. Also, with the increase in minimally invasive surgical techniques, topical hemostasis can aid in fewer transfusions, improved visualization in the surgical field decreased operative time and reduction in the risk of conversion to laparotomy.

show abstract

Section: Hysterectomysupporting

confidence: 86%

Biologic Hemostatic Agents in Obstetrics and Gynecology

Patriarco¹,

Shenoy²,

Taylor³

2021

Contemporary Applications of Biologic Hemostatic Agents Across Surgical Specialties - Volume 2 [Working Title]

View full text Add to dashboard Cite

show abstract

“…Only non‐identifiable data are used for clinical research, and all users of SurgicalPerformance agree that data may be used for research. SurgicalPerformance data has been used previously to analyse the safety of surgical devices and the impact of familiarity of surgical teams . Data for analyses were extracted from the SurgicalPerformance database in December 2018.…”

Section: Methodsmentioning

confidence: 99%

Salpingectomy at the time of hysterectomy for benign gynaecological disease: A comparison of surgical approaches

Obermair

Borg

2019

Aust NZ J Obst Gynaeco

Self Cite

View full text Add to dashboard Cite

Given that a significant percentage of high‐grade serous cancers develop in the fallopian tube, it has been suggested that salpingectomy may prevent some of these malignancies. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists guidelines recommend prophylactic salpingectomy to be discussed with or offered to patients undergoing hysterectomy for benign indications. This study compares rates of salpingectomy at the time of hysterectomy for benign indications across different surgical approaches among Australian and New Zealand gynaecologists. Data were collected via SurgicalPerformance, a web‐based surgical outcomes review and feedback software used by independent gynaecologic surgeons. Of 11 477 hysterectomy records available, 6608 were eligible for analysis. Rates of salpingectomy at vaginal hysterectomy (13%) were significantly lower (P < 0.001) compared to open abdominal (65%), laparoscopic (70%), laparoscopic‐assisted vaginal (78%), or robotic hysterectomies (73%) and also lower than in hysterectomies converted to an open abdominal approach (73%).

show abstract

“…Previous studies performed on immunocompetent patients identifi ed risk factors for abscess formation such as untreated pelvic infl ammatory disease, endometriosis, previous laparotomy and post-operative hematomas [11][12][13].…”

Section: Incorrect Amounts and Disposal Of Hemostatic Agentsmentioning

confidence: 99%

Case Report: Pelvic abscess formation secondary to the use of commercial hemostatic topical agent in an immunocompromised patient?

Monzón-Vargas¹,

Meraz²,

Ayala-Yáñez³

2017

J Gynecol Res Obstet

View full text Add to dashboard Cite

Clinical Group AbstractVarious hemostatic agents are currently available for routine laparoscopic procedures, avoiding thermal lesions due to energy devices and the complexity of intracorporeal sutures, however, evidence of complications in immunocompromised patients is still lacking. We present the case of a severely immunocompromised gynecological patient who underwent a routine laparoscopic cystectomy, where a local hemostatic agent was employed; further complications arose, a second diagnostic laparoscopy revealed a pelvic abscess with severe adhesion formation. All under a complicated clinical setting due to an impaired immune response, whether this abscess was caused due to the hemostatic agent or other patient's conditions remains to be determined, still, various clinical factors and patient's response need to be taken into account as the cause of the abscess formation.

show abstract

Real‐world surgical outcomes of a gelatin‐hemostatic matrix in women requiring a hysterectomy: a matched case–control study

Cited by 7 publications

References 31 publications

Biologic Hemostatic Agents in Obstetrics and Gynecology

Biologic Hemostatic Agents in Obstetrics and Gynecology

Salpingectomy at the time of hysterectomy for benign gynaecological disease: A comparison of surgical approaches

Case Report: Pelvic abscess formation secondary to the use of commercial hemostatic topical agent in an immunocompromised patient?

Contact Info

Product

Resources

About